BUSINESS

• Daiichi Sankyo Grants ROS1/NTRK Inhibitor Rights to AnHeart
  December 19, 2018

• Shionogi Earns CHMP OK for Naldemedine
  December 19, 2018

• Novo Links with H2 Inc. for Diabetes Treatment App
  December 19, 2018

• Takeda, Alphabet's Health Unit Team Up on Japanese Parkinson’s Patient Research
  December 19, 2018

• Adcetris Label Expansion Gets European Panel Nod: Takeda
  December 18, 2018

• Hisamitsu Files Asenapine Transdermal Patch for Schizophrenia in US
  December 18, 2018

• Eisai Grants to Eurofarma Exclusive Rights for Obesity Agent Lorcaserin in Brazil
  December 18, 2018

• Efficacy of Fentos Tape for Cancer Pain in Opioid-Naïve Patients Confirmed in PIII Study: Hisamitsu
  December 17, 2018

• Janssen Applies for Darzalex for Previously Untreated Multiple Myeloma Patients
  December 17, 2018

• Gilead Files HIV Triplet Biktarvy in Japan, JT Pact Termination Set for Jan. 1
  December 17, 2018

• Astellas Makes Full Inroads into I/O Arena with Potenza Buyout
  December 17, 2018

• Lundbeck Japan to Quadruple Workforce by Next Summer, Eyes Vortioxetine Launch: Chief
  December 14, 2018

• Astellas CEO Sees Cell Therapy Biz Model Established by “around 2030”
  December 14, 2018

• ASKA to Review 5-Year Biz Plan after Hit by NHI Price Cut, Despite New Drug Launches
  December 14, 2018

• Daiichi Sankyo Mulling Moving Up DS-8201 Filing to FY2019: Oncology Chief
  December 13, 2018

• Ethical Drug Sales Up 2.0% in October: Crecon
  December 13, 2018

• Otsuka’s US Subsidiary Pulls Plug on License Deal to Sumatriptan Nasal Spray for Acute Migraine
  December 13, 2018

• Eisai, Takeda to Provide Compound Libraries to GARDP for Development of New Antibiotics
  December 13, 2018

• Armed with 2 New Drugs, EA Pharma Looks to Raise Profile in Chronic Constipation Space
  December 12, 2018

• Astellas FLT3 Inhibitor Xospata Now Available in US
  December 12, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 368
• 369
• 370
• 371
• 372
• 373
• 374
• 375
• 376
• …
• Next ›
• 最終 »